Introduction
Approximately 53 900 new cases of non-Hodgkin's lymphoma (NHL) are diagnosed in the US annually. 1 Together, small B-cell lymphomas (SBCLs), including follicular lymphoma (FL), mantle cell lymphoma (MCL), and chronic lymphocytic lymphoma/ small lymphocytic lymphoma (CLL/SLL), comprise one-third of all NHL cases. 2 SBCLs are indolent but generally not curable. 3 The time from diagnosis to death is quite variable, ranging from months to 20 years. 4 Advances in understanding the biological basis and clinical behavior of SBCLs rely on accurate diagnoses. The currently used Revised European-American Lymphoma (REAL) 5 and World Health Organization 6 lymphoma classification systems are based on tumor morphology, molecular abnormalities, and the immunocytochemical measurement of a limited number of leukocyte markers. Using the REAL classification system, there is an approximate 15% interpathologist diagnostic variability rate. 7 A classification scheme based on measuring the expression of a larger number of lymphoma markers, reflecting the complexity of molecular defects in SBCLs, may yield more accurate diagnoses and may guide therapy.
DNA microarrays make it possible to measure in parallel the expression of thousands of individual genes 8 and represent one means to identify new cancer-specific markers. In the area of lymphoma biology, DNA array technology has been used to identify novel markers of SBCLs, including FL, 9 MCL, [10] [11] [12] [13] and CLL/SLL. [14] [15] [16] These analyses have been useful to elucidate specific molecular pathways potentially involved in lymphoma pathogenesis. 17 Further, arrays have been used to identify genes whose patterns of expression identify previously unrecognized but clinically distinct subtypes of diffuse large B-cell lymphoma (DLBCL), [18] [19] [20] [21] MCL, 13 and CLL/SLL. 14, 16 Few published reports have focused on the identification of genes whose expression profiles differ between currently recognized SBCL subtypes. 13, 14, 16, 22 Toward the goal of identifying new SBCL markers, we have used cDNA microarrays to identify genes whose expression patterns differ between benign reactive lymph node tissues (RN) and FL, MCL, and CLL/SLL specimens. We have validated the expression patterns of 23 of these genes using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis, and analyzed the expression of eight genes in a panel of individual lymphoma specimens. Importantly, we have compared our data with publicly available data of other research groups in an attempt to crossvalidate SBCL markers. Genes identified in the course of these studies are of biological interest and represent candidate diagnostic markers.
Materials and methods

Clinical material
Lymph node and lymphoma specimens were obtained from the University of Washington (UW) Hematopathology Laboratory tissue bank. Freshly excised tonsils were obtained from Seattle Children's Hospital and Medical Center. All studies were approved by institutional review boards of the University of Washington Medical Center and Children's Hospital and Regional Medical Center. Between 1989 and 1996, lymph node and lymphoma specimens were surgically removed from patients in the course of their medical care at the UW Medical Center or one of several referral medical facilities in western Washington, Idaho, Montana, and Alaska. Tissues not needed for diagnostic testing were frozen in a water-soluble tissuefreezing medium (OCT; Tissue-Tek, Naperville, IL, USA) and transferred to a À701C freezer, where they were maintained until processing. Each specimen was stripped of patient identifier information with the exception of final diagnosis and anatomic source, and the data were compiled in a computer database. As a result, information such as patient age, sex, stage, symptoms, laboratory parameters, performance status, treatment, and outcome was not available for analysis. Specimens used in this study were identified through a computer-based search for RN, grade I FL (excluding cases noted to be grade II or III), MCL (excluding cases noted to have blastoid morphologic features), and SLL (irrespective of the level of CD38 expression). Cyclin D1 overexpression was validated by immunohistochemistry for a subset of MCL cases (data not shown). Retrospective analysis of flow cytometric data collected at the time of diagnosis for a subset of cases revealed that RN specimens comprised B52% of B cells (n ¼ 4, range 40-65%), FL specimens comprised B64% neoplastic B cells (n ¼ 4, range 50-75%), MCL specimens comprised B72% neoplastic cells (n ¼ 10, range 22-96%), and SLL specimens comprised B75% neoplastic cells (n ¼ 8, range 50-94%) (data not shown). Flow cytometric analysis revealed that tonsil specimens comprised 60-80% B cells; 60-70% of these B cells showed low CD10-positive staining characteristic of follicle center origin (data not shown).
RNA isolation
In all, 18 RN, 21 FL, 25 SLL, and 13 MCL specimens were transferred on dry ice from -701C freezer to a À201C Tissue-Tek II Microtome/Cryostat. Using a cryostat, approximately 50 10-mm tissue sections (representing B250 mg of tissue) were cut from each specimen and placed in a 50 ml conical tube on ice. Fresh tonsil specimens, each in B20 ml RPMI medium (Life Technologies, Rockville, MD, USA), were oriented in plastic Petri dishes with the epithelial side down. Using a scalpel, the tissue was finely chopped against the underside of the epithelial layer to free nonadherent cells into the medium. Cells suspended in the medium were transferred to 50 ml conical tubes, pelleted by centrifugation for 20 min at 800 Â g in an IEC CentraCL centrifuge (International Equipment Company, Needham Heights, MA, USA), and the supernatant was discarded. A sufficient volume (typically 1-5 ml for lymphoma tissue specimens and 5 ml for pelleted tonsil cells) of phenol/guanidine isothiocyanate (TRIzol; Invitrogen Life Technologies, Carlsbad, CA, USA) was added. Samples were vortexed thoroughly and placed on ice for up to several hours. Total RNA was isolated according to the TRIzol manufacturer's instructions and quantified by spectrophotometry 23 using a Hewlett Packard 8452A Diode Array spectrophotometer (Hewlett Packard, Palo Alto, CA, USA). Poly (A) þ mRNA was purified from total RNA using oligo(dT) 25 -linked magnetic beads (Dynal, Oslo, Norway) according to the manufacturer's instructions. RNA was labeled with RiboGreen (Molecular Probes, Eugene, OR, USA) according to the manufacturer's instructions and quantified using a Versafluor fluorometer (Bio-Rad Laboratories, Hercules, CA, USA) by comparison to a standard curve generated using known concentrations of RNA (Molecular Probes). A typical yield from each B250 mg tissue specimen was 0.5-4 mg of mRNA. For array analysis, an equal amount of mRNA was pooled from multiple specimens identified in a footnote to Table 1 . Pooled mRNA was analyzed using an Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). In each case, rRNA contamination was p14% and mRNA migrated as a typical population of species predominantly ranging in size from 1.3 to 4.4 kb (data not shown).
cDNA synthesis, microarray construction, and hybridization Two labeled cDNA populations were prepared from each mRNA pool. In one reaction, 2 mg mRNA were reverse transcribed into cDNA labeled with Cy3-dCTP (AP Biotech, Little Chalfont, Buckinghamshire, UK) as described previously; 24 in a second reaction, 2 mg mRNA were reverse transcribed into cDNA labeled with Cy5-dCTP (AP Biotech). Labeled cDNAs were purified as described previously 24 and dissolved in 100 ml 10 mM Tris, pH 8.0. The efficiency of Cy3/ Cy5-dCTP incorporation was determined using an HP 8452A diode array spectrophotometer and the following formulae: 24 Two sets of slides were used. Human HD-1 and HD-2 arrays each contained nearly unique sets of 7488 cloned human genes and expressed sequence tags (ESTs) spotted in duplicate. A complete list of the genes contained in these arrays is available at http://ra.microslu.washington.edu/ Website/genelist/genelist.html.
Each array was rinsed 10 times in sterile H 2 O and then immediately dried using compressed air. Fluorescently labeled cDNAs were combined as described in the results section, concentrated by drying, resuspended in 20 ml of hybridization solution (50% deionized formamide (Sigma, St Louis, MO, USA), 5 Â SSC (0.75 M sodium chloride, 75 mM sodium citrate; Ambion, Austin, TX, USA), 5 Â Denhardt's solution (Fisher Scientific, Houston, TX, USA), 0.1% sodium dodecyl sulfate (SDS; Ambion, Austin, TX, USA), 100 mg/ml CotI DNA (Invitrogen), and 20 mg/ml polyA [5 0 -A(75)-3 0 ] primer (Invitrogen)), denatured by boiling for 3 min, chilled on ice for 30 s, and placed at room temperature (rt). Labeled cDNAs were added to each array and covered with 64 mm by 25 mm coverslips. Microarrays were hybridized for 14 to 16 h at 421C in a humidified chamber (Genetix Limited, Hampshire, UK). Following hybridization, the microarrays were washed briefly in 1 Â SSC/0.2%SDS (prewarmed to 541C) to remove the coverslips. The arrays were transferred to glass dishes in which they were washed by gentle rocking in 1 Â SSC/0.2% SDS (prewarmed to 541C) for 10 min, 1 Â SSC/0.2% SDS (prewarmed to 541C) for 10 min, 0.1 Â SSC/0.2% SDS (prewarmed to 541C) for 10 min, 0.2 Â SSC (rt) for 1 min, and 0.1 Â SSC (rt) for 1 min. Finally, the arrays were dipped twice in distilled H 2 O and dried with compressed air. The microarrays were scanned at 532 and 633 nm using a Molecular Dynamics Avalanche dual-laser confocal scanner.
Microarray data analysis
Duplicate human HD1 and HD2 slides were hybridized with the same cDNAs, but with the fluorescent labels reversed to correct for dye-specific effects. 26 Each slide contained two identical sets of spots. Two images, each corresponding to one set of spots, were obtained for each slide. Using Spot-On software developed at the UW-CEA, 24 the intensity of each spot (subtracted for local background) in both channels was obtained from each image and exported as a text file. Using GeneSifter. Net TM (VizX Labs, Seattle, WA, USA), the intensity value of each spot in an image was normalized to the mean intensity of all spots in that image. For each IMAGE clone of interest, the gene name, accession number, and functional summary were obtained from public databases using GeneSifter.Nett and the Stanford Online Universal Resource for Clones and ESTs. 27 The raw microarray data from these experiments are available at http://expression.washington.edu/public.
qRT-PCR validation of array data
For confirmation of array data using RNA pooled from multiple specimens (Figures 1 and 2) , an equal amount of mRNA from each specimen was combined as described in the footnotes of Table 1 . PCR mixtures (40 ml) contained 1 Â AmpliTaq Gold Buffer (Applied Biosystems, Foster City, CA, USA), 4 mM MgCl 2 , 0.025 U/ml AmpliTaq Gold (Applied Biosystems), 0.25 U/ml Moloney leukemia virus reverse transcriptase (Invitrogen, Carlsbad, CA, USA), 0.4 U/ml RNase inhibitor (Invitrogen), 0.5 mg/ml BSA (Ambion, Austin, TX, USA), 0.33 Â SYBR Green I (obtained as a 10 000 Â solution from Molecular Probes, Eugene, OR, USA), 0.8 mM passive reference DNA oligohexamer, 5 0 -(6-carboxyrhodamine)-GATTAG-PO 4 -3 0 (Rox Standard I, Synthegen, Houston, TX, USA), 200 mM dNTPs (Amersham Biosciences, Piscataway, NJ, USA), 5 ng mRNA, and 50 nM gene-specific primers (Invitrogen). All gene-specific primers were designed using the computer program Primer Expresst 1.5 (Applied Biosystems) using default settings for RT-PCR primer selection and are listed in Table 2 . Intron spanning primers were selected if splice junctions could be identified using the Ensembl database. 28 Using an ABI 7700 sequence detector (Applied Biosystems), the reactions were subjected to the following cycling conditions: 30 min at 481C, 10 min at 951C, and 40 cycles comprising 15 s at 951C and 1 min at 601C. The relative amount of mRNA in two samples, for example, sample x and sample y, were semiquantified based on the following formula:
where Ct is the number of PCR cycles resulting in a threshold fluorescence level and E, a measure of PCR reaction efficiency, was assumed to be 2 in the exponential phase of PCR product accumulation. For each of the 23 validated genes, array and qRT-PCR data were normalized to the level of gene expression in the tonsil reference RNA pool. A self-organizing map was generated using the default settings of the Cluster analysis program and data were displayed using the Treeview program; both programs were written by Eisen et al. 29 For qRT-PCR analysis of individual specimens (Figure 3 ), variable amounts (p5 ng) of poly(A) þ RNA were used since 5 ng were not available for all cases. In all, 10 cases of RN (RN-1, RN-2, RN-3, RN-4, RN-5, RN-6, RN-7, RN-8, RN-9, and RN-10), nine cases of FL (FL-1, FL-2, FL-3, FL-4, FL-5, FL-6, FL-7, FL-8, and FL-9), nine cases of MCL (MCL-1, MCL-2, MCL-3, MCL-4, MCL-5, MCL-6, MCL-7, MCL-8, and MCL-9), and 10 cases of SLL (SLL-1, SLL-2, SLL-3, SLL-4, SLL-5, SLL-6, SLL-7, SLL-8, SLL-9, and SLL-10) were studied. qRT-PCR was performed as described above, except that in addition, the expression of cyclophilin was determined using primers 5 0 -CCACCGTGTTCTTCGACATTG-3 0 (forward) and 5 0 -TCTTTGGGACCTTGTCTGCAA-3 0 (reverse), and gene expression levels were normalized to cyclophilin expression as follows:
where GOI is the gene of interest (eg 13cDNA73). The cyclophilin gene has been described previously as a useful internal reference RNA. 30 For the purpose of displaying gene expression on a relative scale, the data for each gene were further normalized to the median expression across all individual lymphoma specimens. The raw qRT-PCR data from these experiments are available at http:// expression.washington.edu/public.
Results
cDNA array analysis
The goal of this study was to identify genes whose expression patterns differed between RN, FL, MCL, and SLL. We hypothesized that differentially expressed genes may be involved in lymphoma pathogenesis and serve as useful diagnostic markers. To identify differentially expressed genes, we utilized cDNA microarrays constructed at the UW-CEA. These arrays contained duplicate spots of PCR-amplified insert cDNAs from 14 976 IMAGE clones 25 representing B13 500 individual UniGene clusters. Messenger RNA was purified from archival tissue specimens that had been frozen shortly after their surgical removal and maintained at À701C. As our protocol required a large quantity (2 mg) of mRNA for the synthesis of fluorescently labeled target cDNA for array analysis, we chose to pool equal amounts of mRNA from multiple specimens representing the same tissue type. A similar RNA pooling strategy was shown previously to be useful in identifying genes specifically differentially expressed in colon cancer. 31 Messenger RNA from 17 RN specimens was combined to generate a single pool of RN mRNA. Similarly, we made three additional pools of mRNA from 21 grade I FL specimens, nine MCL specimens, and 25 SLL specimens. Cy3-and Cy5-labeled cDNA was generated from the lymph node and lymphoma mRNA pools. In addition, Cy3-and Cy5-labeled cDNA was generated from RNA pooled from several tonsils for use as a reference control. Sample and reference cDNAs were combined and hybridized to microarrays. All array experiments were performed in duplicate where the labeling scheme was reversed to compensate for potential dye-specific incorporation effects and for dye-dependent nonlinearity of signal intensity. 26 For example, Cy3-labeled lymphoma cDNA and Cy5-labeled tonsil cDNA were hybridized to one array, and Cy5-labeled lymphoma cDNA and Cy3-labeled tonsil cDNA were hybridized to a second array. After hybridization, microarray slides were washed under conditions of increasing stringency and scanned in the Cy3 and Cy5 channels using a laser confocal scanner.
Signal and local background intensities were quantified for each spot on the arrays. Since the majority of IMAGE clones were spotted in duplicate on the arrays and since two arrays were used per sample, four measurements were obtained for most clones. However, some IMAGE clones were represented by more than one set of spots on the arrays. Further, some genes were represented by more than one IMAGE clone. In these cases, statistics for each set of spots were calculated independently. In all, 120 genes were selected that were 44-fold differentially expressed in pairwise comparisons between RN, FL, MCL, and SLL tissues, and showed corresponding two-sided P-values of o0.05 (derived from a t-test analysis assuming equal variances and six degrees of freedom). Table 1 lists the IMAGE Figure 1 Summary flow chart depicting the comparison between gene expression data from microarray and qRT-PCR analyses. The expression of 39 of 120 genes identified by microarray analysis to be 44-fold differentially expressed was quantified by qRT-PCR. Using a threshold of 42-fold differential expression by qRT-PCR analysis, the expression patterns of 23 of the 39 genes were confirmed to be similar both by microarray and qRT-PCR methods. The qRT-PCR product for each of these 23 genes was of expected size by PAGE analysis.
Gene expression analysis in small B-cell lymphomas SC Schmechel et al clone numbers, derived names and accession numbers, and fold differential expression data for these 120 genes; 37 genes uniquely differentially expressed in a single lymphoma subtype vs benign lymph nodes are indicated in bolded italics.
Validation of array results using qRT-PCR
We used the method of qRT-PCR with SYBR Green I dye detection 32 to quantify the relative RNA expression of 39 of the 120 genes. These 39 genes were selected based on their high differential expression by array analysis. qRT-PCR was performed in duplicate on pooled mRNA from multiple RN, FL, MCL, and SLL specimens as described in the footnotes of Table 1 . Oligonucleotide primers used in this qRT-PCR analysis are listed in Table 2 . A flow chart comparing our array and qRT-PCR results is shown in Figure 1 . We found that data for four genes (10% of 39) were not informative, since high signal levels were obtained in no-RT control samples (most likely due to amplification from contaminating genomic DNA rather than from mRNA). Of the remaining 35 genes, 23 (66%) were found by qRT-PCR to be 42-fold differentially expressed in the same direction as the microarray data and to give amplicons that migrated as a single band of expected size by polyacrylamide gel electrophoresis (PAGE) (data not shown). We arbitrarily selected a less stringent two-fold cutoff for differential expression in qRT-PCR analysis rather than the four-fold cutoff used in array analysis. Figure 2 compares our array and qRT-PCR results for these 23 validated genes in pseudocolor graphics where the expression level of each gene in RN, FL, MCL, and SLL is normalized to its expression level in the reference RNA (tonsil) pool.
Our degree of concordance between cDNA array data and qRT-PCR data is in agreement with other investigators, who have found that the expression patterns of approximately twothirds of genes identified using cDNA arrays can be confirmed using qRT-PCR. 32 Discrepancies between array data and qRT-PCR validation data may be due to the misidentification of cDNA molecules spotted on the arrays or due to the amplification of unintended qRT-PCR amplicons. To investigate these two potential sources of error, we performed qRT-PCR analysis on additional genes and identified a total of 24 genes that gave discrepant array and qRT-PCR results (data not shown). We sequenced both the PCR products representing the 24 cDNA array spots and the corresponding 24 amplicons generated using qRT-PCR primers designed to amplify the expected genes. We found that 22 (94%) of 24 qRT-PCR amplicons were of the expected sequence; on the contrary, only one (4%) of 24 PCR products representing cDNA spots was of the expected sequence (data not shown). We concluded that a principal source of discrepancy between array data and qRT-PCR validation data was due to misidentification of cDNA spots on the arrays. The occurrence of spot misidentification has been described by other investigators using cDNA array technology. 33 
qRT-PCR analysis of gene expression in individual specimens
As we used an RNA pooling strategy to identify differentially expressed genes, we were next interested in determining the expression levels of selected validated genes in individual lymphoma specimens. For this analysis, we quantified the level of expression of eight genes (in addition to the cyclophilin gene, which was used as an internal control for normalization) in 10 RN, nine FL, nine MCL, and 10 SLL specimens using qRT-PCR. Data are presented as box plots in Figure 3 to convey the degree of variability in gene expression among specimens. In general, data obtained using individual specimens correlated well with qRT-PCR data obtained using pooled RNA (Figure 2 ).
As expected, we found that CCND1 was overexpressed in each case of MCL relative to other specimen types. On average, CCND1 expression was 28-fold higher in MCL than in RN (P ¼ 0.0003 derived from a t-test analysis assuming equal variances), 40-fold higher than in FL (P ¼ 0.0005), and 33-fold higher than in SLL (P ¼ 0.0003) specimens. DNMT3A, ITM3, and KIAA1407 were also generally overexpressed in MCL. DNMT3A expression in MCL specimens was 4.5-fold higher than in RN (P ¼ 0.0007), 13-fold higher in FL (P ¼ 0.0002), and eight-fold higher than in SLL (P ¼ 0.0001) specimens. ITM3 was expressed in MCL specimens 2.5-fold (P ¼ 0.008), 9.2-fold (P ¼ 0.0003), and 4.4-fold (P ¼ 0.001) than in RN, FL, and SLL specimens, respectively. KIAA1407 was variably expressed in MCL, with some MCL specimens expressing very little of this gene product. On average, KIAA1407 was 21-fold (P ¼ 0.02), 37-fold (P ¼ 0.02), and 3.1-fold (P ¼ NS) overexpressed in MCL specimens than in RN, FL, and SLL specimens, respectively.
KIAA1959 was generally overexpressed in SLL, although the expression of this gene in individual SLL specimens was variable. On average, KIAA1959 was expressed in SLL specimens five-fold (P ¼ 0.02), nine-fold (P ¼ 0.02), and 4.6-fold (P ¼ 0.04) higher than in RN, FL, and MCL specimens, respectively. In agreement with pooled RNA qRT-PCR results, 13CDNA73 was overexpressed in FL and SLL specimens relative to RN and MCL specimens, although there was high variability in the expression of this gene product in FL and SLL tissues. 13CDNA73 was expressed in FL specimens 4.6-fold (P ¼ 0.007) and six-fold (P ¼ 0.006) higher than in RN and MCL specimens, respectively; 13CDNA73 was expressed in SLL 16-fold (P ¼ 0.0003) and 21-fold (0.0004) higher than in RN and MCL, respectively. MYBL2, on the contrary, was more highly expressed in RN and MCL specimens than in FL and SLL. MYBL2 expression in RN specimens was 10-fold (P ¼ 0.0001) and 4.8-fold (P ¼ 0.0002) higher than in FL and SLL; MYBL2 expression in MCL specimens was 7.1-fold (P ¼ 0.0006) and 3.4- Figure 3 Analysis of gene expression in individual specimens of RN, FL, MCL, and SLL. The expression of 13cDNA73, CCND1, DMNT3A, ITM3, KIAA1407, KIAA1959, MGC40441, and MYBL2 in 10 RN, nine FL, nine MCL, and 10 SLL individual specimens was quantified using qRT-PCR. Expression data for each gene were first normalized to the level of cyclophilin expression and subsequently normalized to the median level of expression in all specimens. Box plots are presented, in which the horizontal lines within each box represents the median expression value across all specimens of a tissue type, the lower and upper boundaries of each box represent the 25th and 75th percentile, respectively, whiskers represent either the minimal and maximal values or 1.5 times the spread between the 25th and 75th percentile (whichever is nearer to the body of the data), and circles represent any values outside of the whiskers. Tissue types are identified on the x-axis; relative expression is indicated on the y-axis. RN-1, RN-2, RN-3, RN-4, RN-5, RN-9, RN-10, RN-11, RN-13, RN-15, and RN-17 g IMAGE clones corresponding to these genes were represented by more than one set of spots on the micorarrays; data obtained from only one set of spots gave significant (44-fold, Po0.05) results. h Multiple IMAGE clones corresponding to these genes were represented on the microarrays; data obtained from spots corresponding to only one IMAGE clone gave significant (44-fold, po0.05) results. Genes uniquely over-or underexpressed in one type of lymphoma vs RN tissue shown in bold italics. fold (P ¼ 0.004) higher than in FL and SLL specimens, respectively. Finally, MGC40441 was expressed in RN and FL specimens more highly than in MCL and SLL specimens. MGC40441 was expressed in RN 8.1-fold (P ¼ 0.0007) and six-fold (P ¼ 0.0007) higher than in MCL and SLL specimens, respectively; MGC40441 expression in FL was 6.5-fold (0.001) and 4.8-fold (P ¼ 0.002) higher than in MCL and SLL, respectively.
Comparison with array data obtained by other research groups
It is increasingly appreciated that crossvalidated genes, identified as differentially expressed by independent laboratories performing similar experiments, may represent particularly useful diagnostic markers and therapeutic targets. 34, 35 We thus compared expression data obtained in this study with publicly available data obtained by other research groups who have used arrays to examine SBCL gene expression. [9] [10] [11] [12] [13] [14] [15] For these cross comparisons, we used a feature of GeneSifter.Net TM software that allowed us to cross reference genes in other data sets that were identified by names or accession numbers that differed from the IMAGE clone designations in our data set. In these comparisons, we did not set a minimal fold-differential expression threshold. Rather, we included all genes from our data set that were significantly (Po0.05) differentially expressed between tissue types. Genes showing similar patterns of differential expression in our data set and in publicly available data are shown in Table 3 .
Discussion
Using cDNA microarray analysis, we have identified 120 genes whose expression patterns differed among RN, FL, MCL, and SLL. The differential expression patterns of 23 of these genes were validated using the complementary approach of qRT-PCR. We found that for over one-third of genes analyzed, gene expression patterns obtained using microarrays could not be verified using qRT-PCR, primarily due to cDNA array spot misidentification. The problem of spot misidentification has also been reported by other investigators, stressing the importance of sequencing verifying cDNA clones as a final step prior to printing microarray slides. 33 Among genes identified in this study are genes previously known to be differentially expressed in SBCL, genes known to be involved in cancer types other than lymphoma, genes not previously associated with malignancy, and partially characterized genes/ESTs of unknown function. Much work remains to investigate the potential role of these genes in lymphoma pathogenesis and their potential diagnostic utility. 13CDNA73  GATGACGACAGGCCGATGATT  TGACCAGGACTGCGTTCCATT  APOC2  CCCGCTGTAGATGAGAAACTCA  TCTCCCTTCAGCACAGAAAGAA  BCL2  ATGACTGAGTACCTGAACCGGC  CAGAGACAGCCAGGAGAAATCA  CCL4  CCAGCTGTGGTATTCCAAACCA  TGAGCAGCTCAGTTCAGTTCCA  CCNA2  GCTGGCCTGAATCATTAATACG  GCATGCTGTGGTGCTTTGA  CCND1  AGGTCTGCGAGGAACAGAAGTG  TGCAGGCGGCTCTTTTTCA  CD209L  TGCTGCAACTCCTCTCCTTCAT  CGTCTTGCTCGGATTGTTCCT  CD69  CATGGTGCTACTCTTGCTGTCA  CCCTGTAACGTTGAACCAGTTG  CD86  GGAAAAGACATCAACCCCCATA  TCTGGTTGTGGTCTCTGGTGTT  CLCN4  GCGGCACTGCAGGTGTAATTA  TTCCCTTAGCCAGTCGATGGT  CPNE1  CTGCCTCGCAATACTTCATGCT  CCACACCCACAATGATCACTGA  CRYM  GGCAGGTGCAGATGTGATCAT  TGGCTCCAACAGCATTGATG  CTCF  CACACAGGTACTCGTCCTCACA  TCGCACATGGAACACTTGAA  DNMT3A  CCATTCCTGGTCACGCAAAAC  TCCTGTGTGGTAGGCACCTGAA  FLJ21562  CAGCTGGCTCGATAGTCGTAAA  TCTAGGAGGAGCCCAGTCTTCA  GM2A  AAAAGCCATCCCAGCTCAGTAG  CACATTTCCAGGAACGACGAT  GS3955  AGGAGCTGGTGTGCAAGGTGTT  CCCCATAGCTTCGCTCAAAGAA  IGJ  TCCCATGGCAAGTCCTAAAGC  CCATGACACAGCCAAACAGAAA  IGHM  GCAGCCGGAGAACAACTACAAG  TGCATCACGGAGCATGAGAA  IL24  TCTCATCGTGTCACAACTGCAA  GAGCTGCTTCTACGTCCAACTG  IL4R  CAGCGTTTCCTGCATTGTCATC  GACCCCTGAGCATCCTGGATTA  IMAGE:201981  CCGTCTGTCTCCTTTCCTTCTG  TCCTGTCCTCTGCTCTGTGGAT  IMAGE:258118  TGCTCCCCTGTTTTTGTGACA  TCCTGGAAGTAATGCCAACTCA  ITM3  GGAGCTCCTCATGAACGTGAA  AGGTGTCTTTCCCGTTGCA  JUN  CTAACGCAGCAGTTGCAAACA  TCTCCGTCGCAACTTGTCAA  KIAA0125  ATGGCTCCTGCTGTACCTCAAG  GTGAAGCGGTGGACAAGAAACT  KIAA1350  CGAAGCTGTTGTTCGGAATC  GGCTGGTGTAGCAGATCATACC  KIAA1407  AACCTGCCAGATGCTTGTGAAT  CGGTGTCATCAATTGCTTTGG  KIAA1959  GGTGGATCTGTCAGCTGCCATA  GCCTGTCACCTCAGAACTCCAA  KLF4  GCTCCATTACCAAGAGCTCATG  GTGCCTGGTCAGTTCATCTGA  KRT19  GCATGAAAGCTGCCTTGGAA  CCTGATTCTGCCGCTCACTATC  KRT5  CAGAAGCCGAGTCCTGGTATCA  TGGCGCACTGTTTCTTGACA  LOC51290  AGCAGAAAGAGTGGCAGAGGAT  TTGGTGGAAGAGCTGTTGATGT  MGC40441  GGCCTAGAGCCTCTTGATTCAA  TTGCTCCTCTCACTCCATGTGT  MYBL2  CCCATCAAGAAAGTCCGGAAGT  GCAGTTGTCGGCAAGGATAGA  RNASE1  TCCACTGCATCATTCAGCTTTC  TCTCCAAAGCGAGGTCTTCCT  SF1  AGCTCAGAGACCCGCAGCATTA  ACTGAGGATCACCAGGCCTTTG  SLC2A3  GCCCATCATCATTTCCATTGTG  TGAACACCTGCATCCTTGAAGA  TFAP2C TCGCAAAGGTCCCATTTCC CGTAGAGCTGAGGAGCGACAAT Table 3 Genes showing similar expression patterns in this study and in published data We validated the differential expression of several genes previously known to be involved in SBCLs. Our finding that CCND1 was significantly overexpressed in MCL was not surprising since the overexpression of this cell cycle regulatory protein is important in MCL pathogenesis 36, 37 We found that BCL2 was significantly overexpressed in SLL relative to RN. Since the antiapoptotic BCL2 protein is known to be overexpressed in both FL and SLL, 38, 39 we had expected that BCL2 would also be overexpressed in FL relative to RN and other specimen types. Closer inspection of our array data revealed that BCL2 was 2.3-fold overexpressed in FL relative to RN (P ¼ 0.002) and 1.9-fold overexpressed in FL relative to MCL (P ¼ 0.001). BCL2 was also expressed at a 2.3-fold higher level in SLL than in MCL (P ¼ 0.01). Although these differential expression levels fell below our arbitrarily chosen four-fold stringency threshold, our results agree with the known role of BCL2 in FL and SLL. We found that c-jun was significantly overexpressed in MCL relative to FL, RN, and SLL. c-Jun is an AP-1 transcription factor component known to be overexpressed in the malignant Reed-Sternberg cells that characterize Hodgkin's disease. 40 Lastly, we found that the EST MGC40441, which has also been alternatively referred to as HGAL 21 and GCET2, 41 was overexpressed in RN and FL relative to MCL and CLL. These data complement recent reports that this gene product is relatively overexpressed in FL, purified germinal center B cells, and germinal center B-cell-like (GCB) DLBCL specimens, relative to SLL and MCL specimens. 21, 41 Sequence analysis revealed that MGC40441/HGAL/GCET2 shares 51% identity with the murine germinal center-expressed M17 gene. 21, 42 Interestingly, Lossos et al 21 found that overexpression of this single gene product appears to identify the favorable prognosis GCB subset of DLBCLs. 18, 21 Several of the genes that we identified have well-established roles in cancer types other than lymphoma. We found that c-myb was significantly underexpressed in MCL vs SLL. c-Myb is a member of the myb family of transcription factors that regulates the proliferation, differentiation, and apoptosis of hematopoietic cells and is frequently overexpressed in human myeloid and lymphoid leukemias. 43 To our knowledge, c-myb expression in SBCL lymphomas has not been studied previously. We found that DNA methyltransferase 3A (DNMT3A) was significantly overexpressed in MCL relative to FL and CLL. DNMT3A and DNMT3B are thought to establish cytosine methylation patterns that influence the expression of genes containing upstream CpG islands. 44 DNA from malignant cells often shows global hypomethylation but localized CpG island hypermethylation resulting in the downregulated expression of tumor suppressor genes. 45 DNMT overexpression may contribute to altered DNA methylation patterns in cancer, and CLL cells were recently shown to have increased DNMT3A expression relative to normal lymphocytes. 45 However, no published studies have compared methylation patterns between FL, MCL, and SLL.
The expression patterns of several of the genes that we identified have been studied in cancer, but have no known role in carcinogenesis. We found that CD69 is overexpressed in MCL relative to RN. CD69 is expressed by activated T lymphocytes as well as by malignant FL, MCL, and SLL cells. 46 However, a role for CD69 in lymphoma is unclear and our findings may be explained by the expression of this gene product in T cells contained within MCL specimens. Finally, a large number of identified genes are ESTs of completely unknown function. A large amount of work remains to investigate the biological role and potential diagnostic utility of genes identified in the course of this study. ratios were determined from publicly available data by calculating the ratio of the median expression in CLL/SLL specimens divided by the median expression in FL specimens. 
